摘要
胃癌是世界上最致命的癌症之一,部分胃癌患者的中位总生存期不到12个月。化疗是胃癌的主要治疗手段之一,但细胞毒性药物联合方案并没有从根本上提高化疗有效率。目前,分子靶向治疗已成为胃癌的新治疗手段之一,其治疗策略主要包括:人表皮生长因子受体2(HER2)抑制剂、表皮生长因子受体(EGFR)抑制剂、血管内皮生长因子(VEGF)抑制剂、m TOR抑制剂、c-Met抑制剂、多聚ADP核糖聚合酶抑制剂等。另一方面,我国中医药治疗肿瘤已经取得了相当大的成就,在胃癌的预防和治疗方面展现了其独特的优势,随着对胃癌治疗观念的改变,越来越多的肿瘤患者在接受西医综合治疗同时接受中医药治疗。本文综述了分子靶向治疗与中医药治疗胃癌的最新进展。
Gastric cancer is one of the most fatal cancers in the world. Patients with advanced gastric cancer usually had a median over- all survival time less than 12 months. Although chemotherapy is one of the main therapies for these patients, the combination of cytotoxic drugs does not fundamentally improve the efficiency of chemotherapy. In recent years, molecular targeted therapy has become one of the new therapeutic methods for gastric cancer. The treatment strategies includes inhibitor of HER2, EGFR inhibitor, VEGF inhibitor, mTOR inhibitor, c-Met inhibitor, poly ADP ribose polymerase inhibitor and so on. On the other hand, Chinese medicine has made a great achieve- ment which shows its special advantages in prevention and treatment of gastric cancer. More and more patients accepted traditional Chinese medicine treatment when they got Western medicine treatment. In this paper, we reviewed the progress of molecular targeted therapy and the traditional Chinese medicine treatment for gastric cancer.
出处
《肿瘤药学》
CAS
2017年第2期135-139,163,共6页
Anti-Tumor Pharmacy
基金
国家自然科学基金资助项目(81202730)
关键词
胃癌
靶向治疗
人表皮生长因子受体2
血管内皮生长因子
中医药疗法
Gastric cancer
Molecular targeted therapy
Human epidermal growth factor receptor 2
vascular endothelial growth factor
Chinese medicine therapy
